Clinical Trials
16 trialsNCT03911388 2026-05-15
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05762419 2026-01-28
FUS Etoposide for DMG
Columbia University
Phase 1 Recruiting
NCT05746104 2026-01-22
Second Window Indocyanine Green for All Nervous System Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Enrolling by invitation
NCT00811148 2026-01-13
FCBTR
University of Florida
Recruiting
NCT07098806 2025-08-01
CA2024-LM-001
Plus Therapeutics
Phase 1 Recruiting
NCT00437372 2025-05-02
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Thomas Jefferson University
Phase 1 Completed
NCT04516720 2025-02-12
BDD-NO
Institut du Cancer de Montpellier - Val d'Aurelle
Recruiting
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT00000689 2021-11-02
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT01032200 2021-09-28
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase 2 Completed
NCT00649207 2017-11-21
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie
Phase 1 Completed
NCT01236053 2017-07-06
Cancer in Patients With Gabapentin (GPRD)
GlaxoSmithKline
Completed
NCT02450019 2016-11-15
NeuroVentOR
IRCCS San Raffaele
Phase NA Completed
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed
NCT01579253 2012-12-18
Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients
Ludwig-Maximilians - University of Munich
Unknown